Search


Current filters:



Clear current filters  or Add more filters

View Option



Results 1-10 of 10 (Search time: 0.004 seconds).
  • previous
  • 1
  • next

  Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia (Journal article)

  Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose (Journal article)

  Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome (Journal article)

  Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance (Journal article)

  Clopidogrel vs. aspirin treatment on admission improves 5-year survival after a first-ever acute ischemic stroke. data from the Athens Stroke Outcome Project (Journal article)

  Dose-dependent effect of rosuvastatin treatment on urinary protein excretion (Journal article)

  Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia (Journal article)

  Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study (Journal article)

  Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia (Journal article)

  A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia (Journal article)